Immuneering IMRX 深 沪
等待开盘 08-11 09:30:00 美东时间
4.53
+0.020
+0.44%
华盛通- 最 高4.65
- 今 开4.52
- 成交量 70.68万股
- 最 低 4.51
- 昨 收 4.51
- 总市值 2.93亿
- 52周最高 10.08
- 市盈率 静 --
- 换手率 1.09%
- 52周最低 3.25
- 委 比 94.75%
- 总股本 6469.74万
- 历史最高 33.99
- 量 比 1.08
- 振 幅 3.10%
- 历史最低 1.00
- 每 手 1
- 风险率 1.14%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Stifel analyst Stephen Willey initiated coverage on Lyell Immunopharma Inc (NASDAQ:LYEL) with a B...
08-06 22:12
Immuneering GAAP EPS of -$0.27 in-line
Immuneering press release (IMRX): Q2 GAAP EPS of -$0.27 in-line. Ended Q2 2026 with $182.7 million in cash, cash equivalents and marketable securities with anticipated runway into 2029 More on Immunee...
08-05 19:43
Immuneering Q2 EPS $(0.27), Inline
Immuneering (NASDAQ:IMRX) reported quarterly losses of $(0.27) per share which met the analyst consensus estimate. This is a 32.5 percent increase over losses of $(0.40) per share from the same period last year.
08-05 19:38
Publication in Cancer Research Details Atebimetinib’s Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition
Atebimetinib, a novel MEK inhibitor, demonstrates broad antitumor activity across KRAS-, NRAS-, and BRAF-mutant models, including colorectal, lung, and melanoma cancers, by resisting RAF-mediated bypass signaling. In head-to-head studies, it showed deeper and more durable tumor growth inhibition compared to binimetinib. Preclinical models indicated favorable tolerability, with atebimetinib-treated animals maintaining body weight better than untre...
07-21 20:05
美股大行评级 | 伯恩斯坦上调Robinhood目标价从130美元升至160美元；纽约梅隆银行、Datadog、五三银行、旅行者财产险集团获多家机构上调评级
今日重点评级关注：Needham：维持Immuneering"买入"评级，目标价从11美元升至18美元；富瑞：维持塞德斯医疗"买入"评级，目标价从90美元升至100美元
07-21 11:36
Needham Maintains Buy on Immuneering, Raises Price Target to $18
Needham analyst Ami Fadia maintains Immuneering (NASDAQ:IMRX) with a Buy and raises the price target from $11 to $18.
07-20 18:33
Immuneering Corporation Announces Grants of Inducement Awards
<p>Immuneering Corporation announced on June 15, 2026, that Andrew Gengos was appointed as Chief Financial Officer, effective July 16, 2026. On the same day, Gengos was granted an option to purchase 650,000 shares of the company’s Class A common stock with an exercise price of $4.78 per share. The stock option vests over four years under the 2025 Employment Inducement Award Plan. Additionally, a non-executive employee was granted an option to pur...
07-17 20:05
Cantor Fitzgerald Initiates Coverage On Immuneering with Overweight Rating
Cantor Fitzgerald analyst Li Watsek initiates coverage on Immuneering (NASDAQ:IMRX) with a Overweight rating.
07-08 21:09
Kalaris Appoints Laurie Keating to Board of Directors
Kalaris Therapeutics announced the appointment of Laurie Keating to its Board of Directors, effective August 1, 2026. Keating brings extensive expertise in biotechnology, having previously served in senior roles at Alnylam Pharmaceuticals and Millennium Pharmaceuticals. Her addition is expected to support Kalaris' growth and development of treatments for retinal diseases, including the ongoing clinical trial for TH103, a potential therapy for con...
07-06 20:05
Immuneering Appoints Andrew Gengos CFO, Effective July 16
Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced the appointment of Andrew Gengos as Chief Financial Officer, effective July 16, 2026. Mr. Gengos most recently served as Chief Financial Off...
06-15 19:33
